Nordstrom, J. L., Gay, C. L., Bohac, C., Wahl, A. R., Morgan, T., Schmitz, J. L., … Garcia, J. V. (2022). In vivo preclinical efficacy of MGD014 and MGD020 (HIV-1 envelope x CD3 DART molecules) and first-in-human phase 1 clinical safety evaluation of MGD014. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (Vol. 25, pp. 6–7).

Nordstrom, J. L., C. L. Gay, C. Bohac, A. R. Wahl, T. Morgan, J. L. Schmitz, H. Li, et al. “In vivo preclinical efficacy of MGD014 and MGD020 (HIV-1 envelope x CD3 DART molecules) and first-in-human phase 1 clinical safety evaluation of MGD014.” In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 25:6–7, 2022.

Nordstrom JL, Gay CL, Bohac C, Wahl AR, Morgan T, Schmitz JL, et al. In vivo preclinical efficacy of MGD014 and MGD020 (HIV-1 envelope x CD3 DART molecules) and first-in-human phase 1 clinical safety evaluation of MGD014. In: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2022. p. 6–7.

Nordstrom, J. L., et al. “In vivo preclinical efficacy of MGD014 and MGD020 (HIV-1 envelope x CD3 DART molecules) and first-in-human phase 1 clinical safety evaluation of MGD014.” JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, vol. 25, 2022, pp. 6–7.

Nordstrom JL, Gay CL, Bohac C, Wahl AR, Morgan T, Schmitz JL, Li H, Cotshott J, Gobburu J, Macintyre AN, Gorelick RJ, Ferrari G, Margolis DM, Garcia JV. In vivo preclinical efficacy of MGD014 and MGD020 (HIV-1 envelope x CD3 DART molecules) and first-in-human phase 1 clinical safety evaluation of MGD014. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2022. p. 6–7.